Drugs / Corabotase
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT04752774 | Apr 2021 → Mar 2029 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04821089 | Apr 2021 → Aug 2027 expected | — | Ipsen | Active not recruiting | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT06937931 | Jun 2025 → Mar 2027 expected | cervical dystonia | Ipsen | Recruiting | No outcome recorded |
| Phase 2 | NCT06625060 | Oct 2024 → Oct 2027 expected | migraine disorder | Ipsen | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07779252 | Aug 2026 → Apr 2028 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 3 | NCT07427797 | Feb → Dec 2026 expected | — | Ipsen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07435428 | Feb → Dec 2026 expected | — | Ipsen | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-16 | Ipsen | Results Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction ipsen.com ↗
In the trial, at Week 4, 66% of patients treated with corabotase (50ng) showed a statistically significant ≥2-grade improvement (composite response) vs 0% with placebo, p=0.0001 (primary endpoint). |
| 2025-09-22 | Ipsen | Results Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III ipsen.com ↗
Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs placebo (primary endpoint). |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Corabotase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06937931 ↗ |
| Known as | IPN10200 | “The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to...” NCT04821089 ↗3“The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate...” NCT07427797 ↗ “Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers.” NCT06625060 ↗ |
| Action | Inhibit | “stops the release of these chemical messengers” NCT06625060 ↗ |
| Route | Intramuscular | “Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb.” NCT04752774 ↗ |